# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NextCure (NASDAQ:NXTC) reported quarterly losses of $(11.29) per share which missed the analyst consensus estimate of $(0.39) b...
U.S. stock futures swung between gains and losses on Friday after ending on a mixed note on Thursday. Futures were mixed.
NextCure Inc. (NASDAQ: NXTC) surged by 44.87% in after-hours trading on Thursday, following presentation of new preclinical da...
BELTSVILLE, Md., July 24, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (NASDAQ:NXTC), a clinical-stage biopharmaceutical company com...
Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:NXTC) with a Overweight and lowers the price target from $3...